SynVaccine develops preventive viral vaccines for various major human pathogens. It owns licenses for disruptive technologies that enable the computational rational design of viral genomes and physical DNA editing of viral vaccine genome libraries. Tuval Ben Yehezkel founded SynVaccine in 2013. It has its headquarters in Tel Aviv in Israel.

Biotechnology

Health Care

SynVaccine

SynVaccine's headquarters in Tel Aviv, Israel

The Leadership Team at SynVaccine, comprising the Interim CEO, VP of Synthetic Biology, and CSO, drives strategic direction, oversees R&D initiatives, and manages partnerships and regulatory compliance to advance the development and commercialization of preventive viral vaccines.

Leadership Team

The Advisors Team at SynVaccine provides strategic guidance and expertise in the development of preventive viral vaccines. Composed of experienced professionals, this team offers insights into computational design, DNA editing technologies, regulatory compliance, and market strategies to support the company's mission and growth.

��

People (3)

Jobs (0)

Other teams

Advisors Team

��������

People (3)

Jobs (0)

Other teams

Advisors Team

��